Metraipolis › archive › dc_e1c804277eff

Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse… — Europe PMC PMID:40794709

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40794709
DOI
10.1371/journal.pone.0329385
License (as archived)
solo-consultazione
Archived
2026-11-10T17:03:44.867Z
SHA-256 of the archived text
4973af38c19a217cff598c28ac630cd813a6ed54162c174641e34c4e7c237e26
Stable URL of this page
https://metraipolis.com/documento/dc_e1c804277eff

How to cite

Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse… — Europe PMC PMID:40794709 — Europe PMC (en), https://europepmc.org/article/MED/40794709 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e1c804277eff (Metraipolis archive dc_e1c804277eff, sha256 4973af38c19a217cff598c28ac630cd813a6ed54162c174641e34c4e7c237e26)
BibTeX
@misc{dce1c804277eff,
  title = {Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse… — Europe PMC PMID:40794709},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40794709},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e1c804277eff; sha256 4973af38c19a217cff598c28ac630cd813a6ed54162c174641e34c4e7c237e26},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40794709. Agents can read the archived copy with the MCP tool read_document.